Stocks and Investing
Stocks and Investing
Mon, November 9, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Marc Goodman Maintained (BIIB) at Buy with Decreased Target to $382 on, Nov 9th, 2020
Marc Goodman of SVB Leerink, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $402 to $382 on, Nov 9th, 2020.
Marc has made no other calls on BIIB in the last 4 months.
There are 7 other peers that have a rating on BIIB. Out of the 7 peers that are also analyzing BIIB, 5 agree with Marc's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Colin Bristow of "UBS" Initiated at Hold and Held Target at $268 on, Wednesday, October 28th, 2020
- Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $282 on, Tuesday, October 27th, 2020
- Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $244 on, Thursday, October 22nd, 2020
- Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $265 on, Tuesday, October 20th, 2020
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, September 18th, 2020
These are the ratings of the 2 analyists that currently disagree with Marc
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $350 on, Thursday, October 22nd, 2020
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $357 on, Thursday, October 22nd, 2020
Contributing Sources